Chan YH

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians

SARS-CoV-2 was first detected in late December 2019, however, in the few months that followed, the resultant COVID-19 disease has developed into a devastating pandemic around the world [[1]]. This has led to a race to produce a safe and efficacious vaccine in record time.

Read

Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy

Circulating Ly6Chi monocytes often undergo cellular death upon exhaustion of their antibacterial effector functions, which limits their capacity for subsequent macrophage differentiation. This shrouds the understanding on how the host replaces the tissue-resident macrophage niche effectively during bacterial invasion to avert infection morbidity.

Read

Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study

Host determinants of severe coronavirus disease 2019 include advanced age, comorbidities and male sex. Virologic factors may also be important in determining clinical outcome and transmission rates, but limited patient-level data is available.

Read

Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with a 382-nucleotide deletion (∆382) in the open reading frame 8 (ORF8) region of the genome have been detected in Singapore and other countries. We investigated the effect of this deletion on the clinical features of infection.

Read